Vivas Balcones, Luis DavidBernardo, EstherGarcía Rubira, Juan CarlosAzcona, LuisNúñez Gil, IvanGonzález Ferrer, Juan JoséMacaya Miguel, CarlosAngiolillo, Dominick J.Fernández Ortiz, Antonio Ignacio2024-02-072024-02-072011-10-01Vivas D, Bernardo E, García-Rubira JC, Azcona L, Núñez-Gil I, González-Ferrer JJ, et al. Can resistance to aspirin be reversed after an additional dose? J Thromb Thrombolysis. 2011;32:356-610929-530510.1007/s11239-011-0596-3https://hdl.handle.net/20.500.14352/99946Estudio observacional donde se evaluó en 141 pacientes con enfermedad coronaria estable en tratamiento crónico con aspirina 100mg al día si una dosis adicional reduce el porcentaje de pacientes no respondedores al tratamiento antiagregante. Tras una dosis “extra” de aspirina 100mg, el número de pacientes no respondedores a la inhibición plaquetaria con aspirina se redujo un 15% (del 50,7 al 35%).Aspirin resistance or aspirin non-responsiveness is a recently described phenomenon which has been consistently associated with an increased risk of cardiovascular events. This study was designed to determine the effects of an additional dose of 100 mg of aspirin on platelet function and proportion of aspirin non-responders using the platelet function analyzer-100 (PFA-100), in a well characterized population of stable coronary heart disease patients already on long-term aspirin treatment. Platelet function was assessed using PFA-100 in 141 patients (64.8 ± 10.1 years, 87.9% men) on long-term aspirin treatment (100 mg/day) before and 1 h after “in site” oral aspirin administration (100 mg). Prevalence of aspirin non-responders using PFA-100 was 50.7% (95% confidence interval 42.4–59). One hour after 100 mg of oral aspirin, reassessment of aspirin effects showed a prevalence of non-responders using PFA of 35.0% (95% CI 27.3–43.2) (P < 0.001 vs. pre-dose proportion). Using the PFA-100 system, reassessment of platelet function following oral administration of daily aspirin dosage significantly reduces the number of stable coronary disease patients considered to be non-responders to such treatment.engjournal articlehttps://link.springer.com/article/10.1007/s11239-011-0596-321614455https://pubmed.ncbi.nlm.nih.gov/21614455/restricted access615.212Ciencias Biomédicas32 Ciencias Médicas